Market Share of Malaysia Diabetes Care Drugs Industry
The diabetes drugs market is moderately fragmented, with few significant generic players. A few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb, dominate the insulin drugs and Sglt-2 drugs market. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, players are tapping into new markets to increase their market shares, especially in emerging economies where the demand is very high compared to the supply.
Malaysia Diabetes Drugs Market Leaders
Eli Lilly
Boehringer Ingelheim
Astrazeneca
Sanofi
NovoNordisk
*Disclaimer: Major Players sorted in no particular order
